These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16434464)

  • 1. Insulin sensitivity during combined androgen blockade for prostate cancer.
    Smith MR; Lee H; Nathan DM
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1305-8. PubMed ID: 16434464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
    Smith MR; Lee H; Fallon MA; Nathan DM
    Urology; 2008 Feb; 71(2):318-22. PubMed ID: 18308111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
    Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
    BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
    Smith MR; Lee H; McGovern F; Fallon MA; Goode M; Zietman AL; Finkelstein JS
    Cancer; 2008 May; 112(10):2188-94. PubMed ID: 18348297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.
    Gagliano-Jucá T; Burak MF; Pencina KM; Li Z; Edwards RR; Travison TG; Basaria S
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3900-3908. PubMed ID: 30032274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.
    Hvid T; Winding K; Rinnov A; Dejgaard T; Thomsen C; Iversen P; Brasso K; Mikines KJ; van Hall G; Lindegaard B; Solomon TP; Pedersen BK
    Endocr Relat Cancer; 2013 Oct; 20(5):621-32. PubMed ID: 23744766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
    Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
    J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
    Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
    Ziaran S; Goncalves FM; Breza J
    World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
    Smith MR; Fallon MA; Goode MJ
    Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
    Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
    J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.